2 terminated, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow erteberel: new trials by email Literature Review of erteberel trials Research Report on erteberel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Estrogen Receptor Beta and Mood Estradiol, ER Beta Agonist, Placebo - Perimenopause-Related Depression | Phase 2 | Completed | National Institute of Mental Health (NIMH) | 74 | 2019-05-23 | 2025-09-16 |
| The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia LY500307 150mg, LY500307 75mg, Placebo - Schizophrenia | Phase 2 | Terminated | Indiana University | 95 | 2013-06-01 | 2019-07-02 |
| A Study in Men With Benign Prostatic Hyperplasia LY500307, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Eli Lilly and Company | 414 | 2010-04-01 | 2019-04-08 |
Cognitive Dysfunction (1) · Prostatic Hyperplasia (1) · Schizophrenia (1)
Eli Lilly and Company (1) · Indiana University (1) · National Institute of Mental Health (NIMH) (1)
United States (3) · Australia (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Russia (1)
Alan Breier, MD (1) · Peter J Schmidt, M.D. (1)